ORTHOFIX THIRD QUARTER NON-U.S. SALES GROWTH OF 15% DRIVES OVERALL REVENUE GAIN OF 27.2% TO $12.4 MIL.; LASER INDUSTRIES SALES JUMP 35.5% TO $12.6 MIL.
This article was originally published in The Gray Sheet
Orthofix' sales of products outside the U.S. grew 15% in the third quarter, fueling a 27.2% gain in corporate revenue to $12.4 mil. Among products performing well in non-U.S. markets were the firm's Fracture Fixation System, sales of which "have exceeded expectations," the firm reported.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.